Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Heart RateHeart Rate VariabilityInflammation
Interventions
DRUG

methyl donor

The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.

DRUG

Placebo

Placebo

Trial Locations (1)

M5T 1R4

Gage Occupational and Environmental Health St. Michael's Hospital/University of Toronto, Toronto

All Listed Sponsors
collaborator

University of Toronto

OTHER

collaborator

Unity Health Toronto

OTHER

lead

Harvard School of Public Health (HSPH)

OTHER

NCT01864824 - Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial | Biotech Hunter | Biotech Hunter